Top > Search of International Patents > NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY KIT, AND NUCLEIC ACID DELIVERY METHOD

NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY KIT, AND NUCLEIC ACID DELIVERY METHOD

Foreign code F170009132
File No. S2017-0179-N0
Posted date Jul 20, 2017
Country WIPO
International application number 2016JP067382
International publication number WO 2016199895
Date of international filing Jun 10, 2016
Date of international publication Dec 15, 2016
Priority data
  • P2015-117429 (Jun 10, 2015) JP
Title NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY KIT, AND NUCLEIC ACID DELIVERY METHOD
Abstract The purpose of the present invention is to provide a nucleic acid delivery carrier, a nucleic acid delivery kit, and a nucleic acid delivery method which have an excellent effect of inhibiting cell death after nucleic acid delivery and have excellent efficiency of delivering nucleic acids into cells. This carrier for delivery of nucleic acids into cells comprises a ribosome having a membrane fusion capability, wherein the ribosome includes a cationic lipid as a membrane constituent, and the surface of the ribosome is modified with a temperature-responsive polymer. This nucleic acid delivery carrier is optimally used to deliver nucleic acids into cervical cancer cells. This kit for delivering nucleic acids into cells includes the aforementioned delivery carrier. The nucleic acid delivery method for delivering nucleic acids into cells involves a step for contacting isolated cells with a complex of the aforementioned nucleic acid delivery carrier and nucleic acids, or, a step for dosing a non-human animal with a complex of the aforementioned nucleic acid delivery carrier and nucleic acids.
Outline of related art and contending technology BACKGROUND ART
In gene therapy, nucleic acid such as siRNA intravenous administration alone, and the uptake by the reticuloendothelial system (RES) such as by dissolution with a nuclease, layers and to from blood, such as siRNA into target cells is difficult to reach the nucleic acid. Therefore, more efficient nucleic acid suitable for delivering to the target cell, a drug delivery system is a carrier for (Drug Delivery System: DDS), which is conventionally required.
On the other hand, in recent years, the use of a liposome to DDS has attracted attention. Liposomes, the lipid bilayer cell membrane structure similar to that of the spherical particles, to form a complex with a nucleic acid with nucleic acid can be kept in a stable, also used DDS of the nucleic acid.
For example, lipofectamine (registered trademark) manufactured by Invitrogen (see non-patent document 1) is, and efficiently DDS siRNA into cells can be delivered as a carrier, are used in the related art.
Scope of claims (In Japanese)[請求項1]
膜融合性能を有するリポソームからなる、細胞内への核酸送達用キャリアであって、
前記リポソームは、膜構成成分としてカチオン性脂質を含み、
前記リポソームの表面が温度応答性ポリマーで修飾された、核酸送達用キャリア。
[請求項2]
前記温度応答性ポリマーの水に対する下限臨界溶解温度が35.0~45.0℃である、請求項1に記載の核酸送達用キャリア。
[請求項3]
前記リポソームは、膜構成成分としてリン脂質を含む、請求項1又は2に記載の核酸送達用キャリア。
[請求項4]
子宮頸癌細胞内への核酸の送達に用いられる、請求項1から3のいずれかに記載の核酸送達用キャリア。
[請求項5]
請求項1から4のいずれかに記載の核酸送達用キャリアを含む、細胞内への核酸送達用キット。
[請求項6]
請求項1から4のいずれかに記載の核酸送達用キャリアと核酸との複合体と、単離された細胞とを接触させる工程、又は、
前記核酸送達用キャリアと核酸との複合体をヒトを除く動物に投与する工程を有する、細胞内への核酸送達方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KEIO UNIVERSITY
  • Inventor
  • KANAZAWA, Hideko
  • WANG, Jian
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close